News Archive – March 2019
- Home
- News & Events
- News Archive – March 2019
Posted
29 March 2019
Abstract
Viruses drive carcinogenesis in human cancers through diverse mechanisms that have not been fully elucidated but include promoting immune escape. Here we investigated associations between virus-positivity and immune pathway alteration...
Read more
Posted
29 March 2019
On-line article
The immune response has important roles in the biology of solid tumors, including oncogenesis, tumor growth, invasion and metastasis, and response to treatment. Improved understanding of tumor-immune system interactions has provided promising...
Read more
Posted
29 March 2019
From the British Journal of Cancer
Background
TNM8 staging for oropharyngeal squamous cell carcinomas (OPSCC) surrogates p16 immunohistochemistry for HPV testing. Patients with p16+ OPSCC may lack HPV aetiology. Here, we evaluate the suitability of TNM8 staging for guiding...
Read more
Posted
29 March 2019
European Medicines Agency
This is a summary of the European public assessment report (EPAR) for Erbitux. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and...
Read more
Posted
29 March 2019
Case report from the United States
Methods
We reviewed current statistics and the medical and legal literature regarding inbound medical tourism and the process of obtaining a visa for patients traveling to the United States for medical treatment. To illustrate this process, we...
Read more
Posted
15 March 2019
Scientific Report
Recently, exosomes secreted by menstrual mesenchymal stem cells have been identified as inhibitory agents of tumor angiogenesis and modulators of the tumor cell secretome in prostate and breast cancer. However, their direct effect on endothelial...
Read more
Posted
15 March 2019
News from America
WASHINGTON, D.C. — There’s a new effort on Capitol Hill to make newer cancer treatment options more affordable.
U.S. Senator Tina Smith (D-Minnesota) along with U.S. Senator Jerry Moran (R-Kansas) re-introduced the “Cancer Drug Parity Act”...
Read more
Posted
15 March 2019
A new direction in cancer immunotherapy
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a...
Read more
Posted
15 March 2019
Hopes for earlier diagnosis and better survival outcome in patients with head and neck cancer.
Patients with head and neck squamous cell carcinoma are at increased risk of developing a second primary malignancy, which is associated with poor prognosis and early death. To help improve clinical outcome, we aimed to identify biomarkers for...
Read more
Posted
15 March 2019
Considerable gap in knowledge exists about the mechanisms by which oral tumors regulate peripheral sensory fibers to produce pain and altered sensations. To address this gap, we used a murine model of oral squamous cell carcinoma (OSCC) of the...
Read more
Posted
04 March 2019
Two awards given this year
BAHNO is pleased to announce that, due to the high standard of applications, the Research Committee has decided to make two awards this year.
The recipients are:
Paula Bradley (University of Sunderland) - who will receive £3,000 to develop...
Read more